See more : New Energy Exchange Ltd. (EBODF) Income Statement Analysis – Financial Results
Complete financial analysis of Syndax Pharmaceuticals, Inc. (SNDX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Syndax Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Axis Bank Limited (AXISBANK.NS) Income Statement Analysis – Financial Results
- Modulight Oyj (MODU.HE) Income Statement Analysis – Financial Results
- New Horizon Aircraft Ltd. (HOVR) Income Statement Analysis – Financial Results
- Hohsui Corporation (1352.T) Income Statement Analysis – Financial Results
- D’Ieteren Group SA (SIETY) Income Statement Analysis – Financial Results
Syndax Pharmaceuticals, Inc. (SNDX)
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 139.71M | 1.52M | 1.52M | 1.52M | 2.11M | 1.22M | 627.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 12.00K | 454.00K | 456.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 51.00K |
| Gross Profit | -12.00K | -454.00K | 139.25M | 1.52M | 1.52M | 1.52M | 2.11M | 1.22M | 627.00K | 0.00 | 0.00 | 0.00 | -51.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 99.67% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 163.02M | 118.50M | 88.25M | 50.44M | 42.99M | 60.11M | 48.20M | 31.67M | 9.55M | 10.18M | 3.21M | 5.24M | 6.09M |
| General & Administrative | 0.00 | 33.26M | 25.24M | 22.51M | 16.06M | 17.29M | 15.86M | 13.32M | 11.59M | 11.16M | 5.36M | 3.49M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 66.92M | 33.26M | 25.24M | 22.51M | 16.06M | 17.29M | 15.86M | 13.32M | 11.59M | 11.16M | 5.36M | 3.49M | 3.49M |
| Other Expenses | 0.00 | 2.42M | -1.29M | -1.74M | 1.49M | 1.92M | 1.15M | -706.00K | -37.00K | 4.00K | -3.01M | -1.00K | 0.00 |
| Operating Expenses | 229.95M | 151.76M | 113.49M | 72.94M | 59.06M | 77.39M | 64.06M | 44.99M | 21.14M | 21.33M | 8.57M | 8.73M | 9.57M |
| Cost & Expenses | 229.95M | 151.76M | 113.49M | 72.94M | 59.06M | 77.39M | 64.06M | 44.99M | 21.14M | 21.33M | 8.57M | 8.73M | 9.62M |
| Interest Income | 21.16M | 5.87M | 403.00K | 841.00K | 1.57M | 0.00 | 0.00 | 0.00 | 161.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 208.00K | 3.14M | 1.90M | 2.36M | 1.57M | 1.94M | 1.42M | 956.00K | 1.58M | 0.00 | 0.00 | 0.00 | 1.99M |
| Depreciation & Amortization | 12.00K | 454.00K | 456.00K | 515.00K | 451.00K | 78.00K | 76.00K | 89.00K | 21.00K | 15.00K | 13.00K | 34.00K | 51.00K |
| EBITDA | -229.94M | -151.76M | 27.28M | -70.29M | -55.60M | -73.88M | -61.88M | -43.68M | -20.49M | -21.32M | -8.56M | -5.26M | -11.05M |
| EBITDA Ratio | 0.00% | 0.00% | 18.77% | -4,708.17% | -3,792.95% | -5,001.71% | -2,938.99% | -3,587.38% | -3,248.48% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -229.95M | -151.76M | 26.22M | -71.42M | -57.54M | -75.88M | -61.95M | -43.77M | -20.51M | -21.33M | -8.57M | -8.73M | -9.62M |
| Operating Income Ratio | 0.00% | 0.00% | 18.77% | -4,708.17% | -3,792.95% | -5,001.71% | -2,938.99% | -3,587.38% | -3,271.61% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 20.59M | 2.42M | -1.29M | -1.74M | 1.49M | 1.92M | 1.15M | -706.00K | -3.61M | 1.50M | -5.60M | -1.23M | -3.47M |
| Income Before Tax | -209.36M | -149.34M | 24.93M | -73.16M | -56.05M | -73.96M | -60.80M | -44.47M | -24.12M | -19.83M | -14.17M | -9.97M | -13.09M |
| Income Before Tax Ratio | 0.00% | 0.00% | 17.84% | -4,822.54% | -3,694.59% | -4,875.48% | -2,884.35% | -3,645.25% | -3,846.73% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -5.59M | -43.00K | -89.00K | -92.00K | 1.92M | -76.00K | -89.00K | 1.54M | -1.50M | 2.59M | 1.23M | 0.00 |
| Net Income | -209.36M | -143.75M | 24.93M | -73.07M | -55.96M | -73.96M | -60.80M | -44.47M | -24.12M | -19.83M | -14.17M | -9.97M | -13.09M |
| Net Income Ratio | 0.00% | 0.00% | 17.84% | -4,816.68% | -3,688.53% | -4,875.48% | -2,884.35% | -3,645.25% | -3,846.73% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.98 | -2.37 | 0.48 | -1.77 | -1.84 | -2.92 | -2.90 | -3.04 | -1.39 | -2.07 | -1.77 | -0.14 | -21.11 |
| EPS Diluted | -2.98 | -2.37 | 0.46 | -1.77 | -1.84 | -2.92 | -2.90 | -3.04 | -1.39 | -2.07 | -1.77 | -0.14 | -21.11 |
| Weighted Avg Shares Out | 70.26M | 60.76M | 52.06M | 41.31M | 30.49M | 25.37M | 21.00M | 14.62M | 17.37M | 9.60M | 8.01M | 70.28M | 619.96K |
| Weighted Avg Shares Out (Dil) | 70.37M | 60.76M | 53.62M | 41.31M | 30.49M | 25.37M | 21.00M | 14.62M | 17.37M | 9.60M | 8.01M | 70.28M | 619.96K |
Syndax Announces Updated Data Supporting Impressive Clinical Profile of Revumenib in Genetically-Defined Acute Leukemias to Be Presented at the 65th ASH Annual Meeting
– Additional data from pivotal AUGMENT-101 trial in R/R KMT2Ar acute leukemia further highlight revumenib's potential best-in-class profile – – 100% ORR (n=7) and manageable safety profile observed in Phase 1 results of SAVE trial, an all-oral combination regimen of revumenib...
Syndax to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 2, 2023
WALTHAM, Mass. , Oct. 26, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its third quarter 2023 financial results and provide a business update...
Syndax to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program
– Solidifies first-to-market potential for revumenib – – High unmet need in relapsed or refractory KMT2Ar patients in the U.S. provides a strong foundation for revumenib commercial launch – WALTHAM, Mass. , Oct. 24, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq:...
Syndax: Biotech To Watch With Regulatory Filings Before End Of 2023
Syndax Pharmaceuticals, Inc. reported positive results from its phase 1/2 trial using revumenib to treat relapsed/refractory leukemia patients. The trial met its primary endpoint with a complete remission rate of 23%, significantly higher than the current standard of care. It...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass. , Oct. 6, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on October 1, 2023 the Company granted inducement awards to purchase up to 121,150 shares...
Syndax Pharmaceuticals fall despite positive leukemia
Syndax Pharmaceuticals (NASDAQ:SNDX) Inc (Syndax Pharmaceuticals (NASDAQ:SNDX)) stock was on the back foot on Monday, after reporting results from a leukaemia drug trial which met its primary endpoint. "We are thrilled to report positive results for revumenib in KMT2Ar acute...
Syndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis
– Trial met its primary endpoint with a CR/CRh rate of 23% at interim analysis of the pooled KMT2Ar AML and ALL cohorts (p-value = 0.0036); an additional 14% of patients proceeded to transplant without achieving CR/CRh – – 65%...
SmileDirectClub shares plunge after bankruptcy filing, with Syndax and AMC shares climbing and other active stocks
Syndax Pharmaceuticals Inc. SNDX, -7.10% rose 19% in premarket trading. The clinical stage biopharmaceutical company said late Friday that it would release topline results from its trial of Revumenib to treat certain forms of leukemia.
Syndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023
WALTHAM, Mass. , Sept. 29, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and live webcast to share topline results from...
Syndax Pharmaceuticals: Positive Axatilimab Phase 2 Results
Syndax is making strides in the adoption of entinostat, a cancer therapeutic used in combination with immune checkpoint therapies. Syndax reported an increase in operating expenses in Q2 2023, but remains financially stable with cash reserves of $418.3 million. Syndax...
Source: https://incomestatements.info
Category: Stock Reports